Harish Seethamraju, M.D., Medical Director for the
Post# of 148169
(Total Views: 539)
Posted On: 03/06/2021 9:24:53 AM
Harish Seethamraju, M.D., Medical Director for the Mount Sinai Lung Transplantation Program, commented, “The CD12 trial results are very promising and leronlimab may be the only safe medication to help critically ill patients.”
In my opinion (and Dr Seethamraju's), this says it all. Clearly the medical community interprets the CD12 results as "very promising", and I doubt the FDA sees it differently.
In my opinion (and Dr Seethamraju's), this says it all. Clearly the medical community interprets the CD12 results as "very promising", and I doubt the FDA sees it differently.
(6)
(0)CytoDyn Inc (CYDY) Stock Research Links
My comments are just my opinions and should NOT be taken as investment advice.
Scroll down for more posts ▼